CAR T-CELL THERAPY MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-187767 | Pharmaceuticals and Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
CAR T-Cell Therapy Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL CAR T-CELL THERAPY MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL CAR T-CELL THERAPY MARKET
7.1 GLOBAL CAR T-CELL THERAPY MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL CAR T-CELL THERAPY MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL CAR T-CELL THERAPY MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE CAR T-CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE CAR T-CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC CAR T-CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC CAR T-CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Celgene (Juno Therapeutics)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Novartis
16.3 Gilead (Kite Pharma)
16.4 Pfizer
16.5 CARsgen Therapeutics
16.6 Autolus Therapeutics
16.7 Aurora BioPharma
16.8 Sorrento Therapeutics
16.9 Mustang Bio
16.10 Bluebird Bio
16.11 Collectis
16.12 Allogene Therapeutics
16.13 Celyad
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeAllogeneic
Autologous
By Application
Hospitals
Cancer Research Centers
Companies
Celgene (Juno Therapeutics)
Novartis
Gilead (Kite Pharma)
Pfizer
CARsgen Therapeutics
Autolus Therapeutics
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Collectis
Allogene Therapeutics
Celyad
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.